Kidney conditions: CKD and renin–angiotensin system antagonists

This indicator covers the percentage of patients on the CKD register who have hypertension and an ACR over 30mg/mmol  and who are currently being treated with an angiotensin-receptor blocker or an angiotensin-converting enzyme inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

Last reviewed: 15 October 2026

We updated the wording of the indicator, replacing 'proteinuria' with 'an ACR over 30 mg/mmol' in line with NICE’s guideline on chronic kidney disease on the use of ACEi and ARB.

Next review: 30 March 2029

This indicator will be reviewed using the assessment criteria in appendix A of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

This indicator was previously published as NM84.

How to use NICE indicators and how we develop them

Indicators can be used in a number of different settings to support high quality care. These include:

• identifying where improvements are needed
• setting priorities for quality improvement and support
• creating local performance dashboards
• benchmarking performance against national data
• supporting local quality improvement schemes
• showing progress that local health systems are making on outcomes.

Find out how to use indicators and how we develop them.